Alcon Vigamox for conjunctivitis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alcon receives approval April 15 for its ophthalmic antibiotic Vigamox (moxifloxacin ophthalmic solution 0.5%) for treatment of bacterial conjunctivitis. The fluoroquinolone antibiotic received a priority review. Alcon says that moxifloxacin's high solubility allows for formulation at a higher concentration than other fourth generation fluoroquinolones. The firm also is touting the agent's "near-neutral pH, resulting in a low incidence of [ocular] stinging." Launch is expected in Ma